HAN MI PHARMA CO LTD

Hanmi Pharmaceutical Co., Ltd. is a manufacturer.

Company Profile:

Country: South Korea

Company Type: Manufacturer (Pharmaceutical Company)

Overview:

Hanmi Pharmaceutical Co., Ltd. is a prominent South Korean pharmaceutical company committed to enhancing global health through innovative research, development, manufacturing, and marketing of a comprehensive range of pharmaceutical products. Founded in 1973, the company has established itself as a significant leader in both the domestic and international pharmaceutical industries.

Key Activities:

Hanmi Pharmaceutical's core operations span the entire pharmaceutical value chain:

1. Research and Development (R&D): The company places a strong emphasis on R&D, dedicating substantial resources to discover and develop novel drugs across various therapeutic areas, including oncology, metabolic diseases (such as diabetes), autoimmune disorders, and rare diseases. It is particularly known for its expertise in developing fixed-dose combination drugs and modified-release formulations.

2. Manufacturing: Hanmi operates state-of-the-art manufacturing facilities that adhere to stringent international quality standards, including cGMP (current Good Manufacturing Practice). These facilities produce a wide array of ethical drugs (prescription medications), over-the-counter (OTC) drugs, and health functional foods.

3. Marketing and Sales: The company is responsible for the marketing and distribution of its products to hospitals, clinics, pharmacies, and directly to consumers throughout South Korea, and also through strategic partnerships worldwide.

Innovation and Global Reach:

Hanmi Pharmaceutical is celebrated for its robust R&D capabilities and has a history of successfully licensing out its proprietary technologies and drug candidates to major multinational pharmaceutical companies. This underscores its strong global competitiveness and commitment to innovation. The company's mission is driven by a dedication to science and patient-centric solutions, aiming to provide effective and safe healthcare options to improve lives.

HAN MI PHARMA CO LTD Products:

* **APOQUEL (oclacitinib)**: Treatment of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.

* **ROSULIB (rosuvastatin)**: Treatment of hyperlipidemia.

* **AMODIPINE (amlodipine besylate)**: Treatment of hypertension and angina.

* **HANMI Flu Vaccine**: Seasonal influenza vaccine.

* **ECOSEPT (esomeprazole)**: Treatment of gastroesophageal reflux disease (GERD).

* **LUCENTIS (ranibizumab)**: Treatment of neovascular (wet) age-related macular degeneration (AMD). (Distribution Agreement)

* **Various Cephalosporin Antibiotics**: Injectable antibiotics.

* **Diabetes Treatments**: A range of diabetes medications, including oral and injectable treatments.

* **HANMI Pantoprazole**: Treatment of acid-related gastrointestinal disorders.

* **MM-141/SAR408701**: Investigational cancer therapy. (Collaboration)

* **Poziotinib**: Investigational cancer therapy. (License Agreement with Spectrum Pharmaceuticals)

* **Oraxol**: Oral paclitaxel formulation for cancer treatment.

* **Rolontis (eflapegrastim)**: Neutropenia treatment.

* **BELRAPIBE (beloranib)**: Investigational obesity treatment (Development Discontinued).

* **HM15211**: Investigational long-acting GLP-1/GIP/GCG triple agonist for diabetes and obesity.

* **HM15136**: Investigational long-acting GLP-1 receptor agonist for diabetes and obesity.

* **Other Pharmaceutical Products**: A wide range of prescription and over-the-counter medications.